follow earn callback abbott want pass along interest takeaway
overal result disappoint slightli organ top-lin print versu hope view
compani organ growth outlook ahead expect import take-away
posit abbott stori even rais outlook see clear pathway abbott come high
end rang back sever meaning product launch come includ us launch
alin midyear continu strength freestyl libr libr roll europ mitraclip
alreadi see benefit septemb coapt data strong importantli compani
bake contribut expans fmr indic current outlook bottom line compani
guidanc line expect inclus headwind fx exclud
compani point anoth year mid-teen ep growth remain best class large-cap
med-tech group provid granular segment-level takeaway manag discuss today
cadenc top line organ sale come organ growth right
around slightli given easier comp fx headwind year bulk
hit ep line gm think bottom-lin progress year could
look like low mid low mid back fx get
us steadi ep growth y/i quarter
 updat look oper line item interest expens settl
rang compani benefit debt pay-down effort amount north
cours bring abbott net debt/ebitda versu follow execut
st jude aler deal compani expect fx gains-to-loss line item neutral full
year incom expect tick result increas pension
incom fund area favor discount rate tax abbott reiter
expect rate fairli consist quarter
capit alloc come morn earn call degre investor interest focus commentari
ceo mile white compani isnt interest execut today environ noth
interest buy continu see abbott capit alloc prioriti invest organ pipelin
opportun translat compani meaning growth driver includ alin
freestyl libr mitraclip pay debt even today lower level share buyback
note share buyback distant manag initi outlook share
repurchas assumpt bake even off-set dilut
establish pharmaceut head abbott decid discontinu busi non-cor
distributor busi compani emerg market unit strateg move hit sale
per quarter point epd growth importantli zero
impact abbott bottom line given repres smaller countri market oper close zero
nutrit third quarter abbott exit ea us adult nutrit brand account sale
go forward abbott remov ea organ growth calcul discontinu
oper model headwind compani
lap discontinu exclud impact abbott expect nutrit franchis deliv low- mid-single-
digit growth full year
diagnost diagnost continu area see potenti signific upsid head
beyond back alin multi-year roll-out recoveri legaci aler rapid diagnost busi
intern alin sale came north launch even alin come
us compani abl grow us lab twice rate overal market part
driven knowledg custom renew anticip alin still expect growth
us broadli acceler platform launch start midyear
abbott legaci point busi one area disappoint declin
manag comment hasnt happi perform made key
leadership chang reinvigor growth immedi turnaround expect busi pivot
flat back half year
diagnost finish year strong early-season flu benefit compani seen tailwind
moder see area drag overal growth full year difficult flu comp
busi remain turnaround mode
heart failur follow abbott octob fda approv heartmat lvad use destin
therapi dt treatment manag confirm take share market broadli
compani see dt repres market challeng bridge-to-transpl btt indic
account benefit abbott ramp dt outlook heartmat solid
growth mostli come result share captur versu market acceler
rhythm manag sale organ declin came model
high power power devic face declin high power sale us ou came
expect defibril sale fell short us vs estim vs
repres anoth q/q declin due share loss power sale us ou came
estim includ ou pacemak miss vs jpme crt-p
miss vs jpme
electrophysiolog js ep busi moder somewhat quarter organ still point toward healthi
market growth unsurpris abbott follow strong quarter ablat cathet
diagnost particular strong quarter growth respect bake
growth seen quarter abbott ep busi grown organ full year meaning step
low-double-digit rang seen year icm side busi sale fell
expect us advanc map sale also soft keep mind
tacticath contact forc ablat cathet sensor enabl launch januari
vascular de sale softer expect us sale line expect
ou sale come endovascular soft quarter well sale
quarter come model y/i declin partial caus difficult comp
structur heart busi bright spot quarter mitraclip acceler growth us ou
sale respect manag specif call tailwind
coapt data present septemb continu see mitraclip one signific area upsid
abbott overal time formal function mitral regurgit fmr label question abbott reiter
expect summer approv morgan healthcar confer time reimburs
remain major unknown like come late small chanc could grant reimburs
approv concurr fda approv elsewher structur heart surgic valv declin
portico tavr valv roughli flat
neuromodul right tail nan abbott neuromodul busi post signific disappoint
growth organ led miss despit easier comp unsurpris
busi would slow compani lap launch burst sale us
ou grew report miss expect closer take account fact
sever competitor alreadi pre-announce better expect result neuro busi
other reiter belief double-digit growth read-through seem competit dynam
market dynam impact abbott drg side sale disappoint come
model outsid drg nerv ablat also declin quarter
deep brain stimul db grew close sale
diabet libr stori continu impress us sale libr roughli us compar
manag also spoke libr begin differenti insur plan thu
reduc out-of-pocket cost patient highlight pbm libr classifi tier product
higher reimburs versu classifi tier dont see headwind
isnt compet price pariti importantli isnt exclud plan slightli higher cost ou sale
also higher estim roughli flat impli ex-freestyl libr
base busi post roughli sale quarter continu declin expect libr busi
continu build momentum look manag expect growth broader diabet
busi step organ growth saw inevit result libr scale
analyst certif author name within report research analyst unless otherwis specifi research analyst
denot ac cover report certifi multipl research analyst primarili respons report
research analyst denot ac cover within document individu certifi respect secur issuer
research analyst cover research view express report accur reflect person
view subject secur issuer part research analyst compens
directli indirectli relat specif recommend view express research analyst report
korea-bas research analyst list front cover also certifi per kofia requir analysi made
good faith view reflect opinion without undu influenc intervent
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
market maker/ liquid provid morgan and/or affili market maker and/or liquid provid financi
instrument of/rel
lead co-manag morgan act manag co-manag public offer secur financi instrument
term defin direct within past month
client morgan current within past month follow entiti client
client/invest bank morgan current within past month follow entiti invest
client/non-invest bank securities-rel morgan current within past month follow
entiti client servic provid non-investment-bank securities-rel
client/non-securities-rel morgan current within past month follow entiti client
servic provid non-securities-rel
invest bank past month morgan receiv past month compens invest bank servic
invest bank next month morgan expect receiv intend seek compens invest bank
servic next three month
non-invest bank compens morgan receiv compens past month product servic
invest bank
debt posit morgan may hold posit debt secur
company-specif disclosur import disclosur includ price chart credit opinion histori tabl avail
compendium report morgancov compani visit http //www jpmm com/research/disclosur call
e-mail request morgan strategi technic quantit
research team may screen compani cover morgan import disclosur compani pleas call
email
bloomberg morgan price data adjust stock split dividend
initi coverag jan share price market close previou busi day
chart show morgan continu coverag stock current analyst may may cover entir
 morgan rate design ow overweight neutral uw underweight nr rate
explan equiti research rate design analyst coverag univers
 morgan use follow rate system overweight next six twelv month expect stock outperform
averag total return stock analyst analyst team coverag univers neutral next six twelv
month expect stock perform line averag total return stock analyst analyst team
coverag univers underweight next six twelv month expect stock under-perform averag total return
stock analyst analyst team coverag univers rate nr morgan remov rate
applic price target stock either lack suffici fundament basi legal regulatori polici
reason previou rate applic price target longer reli upon nr design
recommend rate asia ex-australia ex-india small- mid-cap equiti research stock expect
total return compar expect total return benchmark countri market index analyst coverag univers
appear import disclosur section report certifi analyst coverag univers found
